Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

The advisory committee, which met at the FDA’s request Thursday, did not reach a conclusion about the cause of a safety ...

A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...

The FDA has since put a hold on enrolling children under 2 years old and those ages 2 through 5 who have never been exposed ...

FDA advisors said that more data are needed to fully understand if there are broader safety concerns related to use of ...

Ahead of an advisory committee meeting later this week, the FDA revealed that all studies for RSV vaccines in young children ...

The FDA has placed a hold on all clinical studies of vaccines for respiratory syncytial virus in infants due to safety concerns following a trial involving two mRNA-based vaccine candidates from ...

Endpoints Weekly covers ASH conference highlights, FDA discussions on Moderna's RSV vaccine safety, Biosecure Act exclusion, and industry updates from biotech leaders.

In the chaotic early days of the pandemic, Wall Street scrambled to place bets on the companies that looked the most likely ...

The S&P 500 fell 0.3% on Tuesday, Dec. 10, as the cooldown from last week's record-setting rally continued ahead of key ...

The Southern Hemisphere’s only mRNA manufacturing facility has opened in Victoria to ensure world-class mRNA vaccines and ...